Vincerx Pharma (VINC)
(Delayed Data from NSDQ)
$0.70 USD
-0.01 (-0.70%)
Updated Sep 13, 2024 03:57 PM ET
After-Market: $0.70 0.00 (-0.61%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.70 USD
-0.01 (-0.70%)
Updated Sep 13, 2024 03:57 PM ET
After-Market: $0.70 0.00 (-0.61%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Zacks News
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
by Zacks Equity Research
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.